[
  {
    "ts": "2026-02-19T12:00:00+00:00",
    "headline": "Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",
    "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adminis",
    "url": "https://finance.yahoo.com/news/garetosmab-biologics-license-application-accepted-120000892.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c7f3fcfc-707a-3f78-abdc-495acf4c5744",
      "content": {
        "id": "c7f3fcfc-707a-3f78-abdc-495acf4c5744",
        "contentType": "STORY",
        "title": "Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",
        "description": "",
        "summary": "FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adminis",
        "pubDate": "2026-02-19T12:00:00Z",
        "displayTime": "2026-02-19T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/garetosmab-biologics-license-application-accepted-120000892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/garetosmab-biologics-license-application-accepted-120000892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T13:21:00+00:00",
    "headline": "AtaiBeckley names Michael Faerm as finance chief",
    "summary": "AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087626/ataibeckley-names-michael-faerm-as-finance-chief-1087626.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "a9216f54-adc1-3f8d-bcfa-3b88463f69cb",
      "content": {
        "id": "a9216f54-adc1-3f8d-bcfa-3b88463f69cb",
        "contentType": "STORY",
        "title": "AtaiBeckley names Michael Faerm as finance chief",
        "description": "",
        "summary": "AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...",
        "pubDate": "2026-02-19T13:21:00Z",
        "displayTime": "2026-02-19T13:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/b0ddfb07fcad8cebccaf61345fd8d80f",
          "originalWidth": 1079,
          "originalHeight": 720,
          "caption": "AtaiBeckley names Michael Faerm as finance chief",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U44frEVc3FCr.t_jha6GsQ--~B/aD03MjA7dz0xMDc5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/proactive_us_504/b0ddfb07fcad8cebccaf61345fd8d80f.cf.webp",
              "width": 1079,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbWWPr49TzCi7fD317UdIA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/b0ddfb07fcad8cebccaf61345fd8d80f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087626/ataibeckley-names-michael-faerm-as-finance-chief-1087626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ataibeckley-names-michael-faerm-finance-132100371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ATAI"
            },
            {
              "symbol": "VIRX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "INVA"
            },
            {
              "symbol": "ARTV"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T14:53:40+00:00",
    "headline": "Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts […]",
    "url": "https://finance.yahoo.com/news/analysts-saying-regeneron-pharmaceuticals-regn-145340699.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a1cc6bb3-c2c8-3c51-a918-d84cd450aa7e",
      "content": {
        "id": "a1cc6bb3-c2c8-3c51-a918-d84cd450aa7e",
        "contentType": "STORY",
        "title": "Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts […]",
        "pubDate": "2026-02-19T14:53:40Z",
        "displayTime": "2026-02-19T14:53:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Regeneron (REGN) Draws Higher Target From TD Cowen",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYTEe3VE6sgZxe9COOwZXw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ku0XeMdDvNCP8FVlwzrrCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-regeneron-pharmaceuticals-regn-145340699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-regeneron-pharmaceuticals-regn-145340699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]